Turakhia et al., The American Journal of Cardiology, 2013

Diagnostic utility of a novel leadless arrhythmia monitoring device.


Yaw Adjei-Poku, MD
Device Clinic Medical Director at New Mexico Heart Institute

Want to read the full article?

Excerpt from:
The American Journal of Cardiology

Although extending the duration of ambulatory electrocardiographic monitoring beyond 24 to 48 hours can improve the detection of arrhythmias, lead-based (Holter) monitors might be limited by patient compliance and other factors. We, therefore, evaluated compliance, analyzable signal time, interval to arrhythmia detection, and diagnostic yield of the Zio patch, a novel leadless, electrocardiographic monitoring device in 26,751 consecutive patients.

The mean wear time was 7.6 ± 3.6 days, and the median analyzable time was 99% of the total wear time. Among the patients with detected arrhythmias (60.3% of all patients), 29.9% had their first arrhythmia and 51.1% had their first symptom-triggered arrhythmia occur after the initial 48-hour period. Compared with the first 48 hours of monitoring, the overall diagnostic yield was greater when data from the entire Zio patch wear duration were included for any arrhythmia (62.2% vs 43.9%, p <0.0001) and for any symptomatic arrhythmia (9.7% vs 4.4%, p <0.0001). For paroxysmal atrial fibrillation (AF), the mean interval to the first detection of AF was inversely proportional to the total AF burden, with an increasing proportion occurring after 48 hours (11.2%, 10.5%, 20.8%, and 38.0% for an AF burden of 51% to 75%, 26% to 50%, 1% to 25%, and <1%, respectively).

In conclusion, extended monitoring with the Zio patch for ≤14 days is feasible, with high patient compliance, a high analyzable signal time, and an incremental diagnostic yield beyond 48 hours for all arrhythmia types. These findings could have significant implications for device selection, monitoring duration, and care pathways for arrhythmia evaluation and AF surveillance.


Author affiliations: "Dr. Kumar is the founder and former chief medical officer of iRhythm Technologies, Inc. (San Francisco) and retains a significant equity share in the company.”

Funding: “This project was supported by a grant from iRhythm Technologies, Inc. (San Francisco, CA). Dr. Turakhia is supported by Veterans Health Services Research and Development Career Development Award CDA09027-1 (Washington, DC) and American Heart Association National Scientist Development grant 09SDG2250647 (Dallas, Texas).”

Let's talk.

We'd love to know how we can help you and your patients.
Reprinted from The American Journal of Cardiology, 112/4, Turakhia MP, Hoang DD, Zimetbaum P, et al., Diagnostic utility of a novel leadless arrhythmia monitoring device, 520-524, copyright 2013, with permission from Elsevier.